Intrexon Receives a Buy from JMP Securities

By Ryan Adsit

JMP Securities analyst Jason Butler reiterated a Buy rating on Intrexon (NYSE: XON) today. The company’s shares opened today at $28.14.

According to, Butler is a 4-star analyst with an average return of 3.8% and a 50.0% success rate. Butler covers the Healthcare sector, focusing on stocks such as Flamel Technologies S.A., Intra-Cellular Therapies, and ACADIA Pharmaceuticals.

Intrexon has an analyst consensus of Moderate Buy.

The company has a one year high of $41.82 and a one year low of $18.52. Currently, Intrexon has an average volume of 1.3M.

Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of XON in relation to earlier this year.

Intrexon Corp. is a biotechnology company focused on collaborating with companies in health, food, energy and the environment to create biologically based products. The company is engaged in the field of synthetic biology, which is an emerging discipline that applies engineering principles to biological systems. It designs, builds and regulates gene programs, which are DNA sequences that consist of key genetic components by using its suite of proprietary and complementary technologies. The company offers UltraVector proprietary technology platforms for the design, creation, modification, and regulation of complex gene programs and cellular systems at commercial scale; and RTS technology, which provides inducible control over the level and timing of gene expression and is part of an UltraVector library of various diverse modular genetic components. Intrexon was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.